Sevelamer Carbonate

The dosage of Sevelamer Carbonate is highly individualized and is based on the patient's current serum phosphorus levels. Healthcare providers typically follow a standardized starting regimen:

• Serum Phosphorus > 5.5 and < 7.5 mg/dL: The recommended starting dose is 800 mg (one tablet or one 0.8 g packet) taken three times daily with meals.
• Serum Phosphorus ≥ 7.5 and < 9.0 mg/dL: The recommended starting dose is 1,600 mg (two 800 mg tablets or two 0.8 g packets) taken three times daily with meals.
• Serum Phosphorus ≥ 9.0 mg/dL: The recommended starting dose is 2,400 mg (three 800 mg tablets or one 2.4 g packet) taken three times daily with meals.

For patients switching from Sevelamer Hydrochloride to Sevelamer Carbonate, the dose is usually transitioned gram-for-gram. For patients switching from calcium-based binders, the dose is titrated based on phosphorus levels.

Sevelamer Carbonate is approved for use in children aged 6 years and older. The dosage is determined by Body Surface Area (BSA):

• BSA ≥ 0.75 to < 1.2 m²: Starting dose is 800 mg three times daily with meals.
• BSA ≥ 1.2 m²: Starting dose is 1,600 mg three times daily with meals.

Titration in children follows the same logic as in adults, with adjustments made every 1-2 weeks until target phosphorus levels are achieved.

Renal Impairment

Since Sevelamer Carbonate is used specifically for patients with severe renal impairment (dialysis), no further dose adjustment is needed based on the degree of kidney failure. However, the dose must be constantly titrated based on the clinical response (serum phosphorus levels).

Hepatic Impairment

Because Sevelamer Carbonate is not absorbed or metabolized by the liver, no dosage adjustments are required for patients with hepatic impairment.

Elderly Patients

Clinical trials did not identify significant differences in safety or efficacy between patients over 65 and younger patients. Dose selection should be cautious, starting at the lower end of the dosing range, reflecting the greater frequency of decreased GI motility in this population.

To achieve maximum efficacy, Sevelamer Carbonate must be taken with meals. It works by binding the phosphorus in the food you are currently eating; taking it on an empty stomach significantly reduces its effectiveness.

• Tablets: Swallow the tablets whole. Do not crush, chew, or break them, as the polymer can expand in the esophagus and cause a choking hazard or irritation.
• Powder: Empty the contents of the packet into a cup and mix with the prescribed amount of water (usually 30 to 60 mL). Stir well and drink immediately. The powder does not dissolve; it forms a suspension. If any residue remains in the glass, add more water, swirl, and drink to ensure the full dose is consumed.
• Storage: Store at room temperature (25°C or 77°F), protected from moisture and heat.

If you miss a dose of Sevelamer Carbonate, skip the missed dose and take your next dose with your next meal. Do not take two doses at once to make up for a missed one. Since the drug only works when food is present in the gut, taking a dose between meals is generally not beneficial.

Because Sevelamer Carbonate is not absorbed, systemic toxicity from an overdose is unlikely. However, taking excessively large amounts may lead to severe constipation or gastrointestinal obstruction. If an overdose is suspected, or if the patient experiences severe abdominal pain or inability to have a bowel movement, contact a poison control center or seek emergency medical attention immediately.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this can lead to rapid increases in phosphorus levels.

Because Sevelamer Carbonate acts locally within the digestive tract, the most frequent side effects are gastrointestinal in nature. According to clinical trial data, more than 10% of patients may experience:

• Nausea and Vomiting: This is often most pronounced when starting the medication or during dose increases. Taking the medication exactly as directed with food can help mitigate these symptoms.
• Diarrhea: Some patients report loose stools, which may be related to the way the polymer interacts with the gut flora or bile acids.
• Dyspepsia (Indigestion): A feeling of fullness or burning in the upper abdomen.
• Abdominal Pain: General discomfort or cramping in the stomach area.
• Flatulence (Gas): Increased gas production is a common complaint as the body adjusts to the polymer.

• Constipation: While some experience diarrhea, others may find that the polymer slows down bowel movements. This can be particularly problematic for dialysis patients who are often on fluid-restricted diets.
• Gastroesophageal Reflux Disease (GERD): Heartburn or the backup of stomach acid into the esophagus.
• Pruritus (Itching): While itching is common in dialysis patients (uremic pruritus), some patients report an increase when starting Sevelamer.

• Intestinal Obstruction: A rare but serious blockage of the bowel.
• Fecal Impaction: Severe constipation where stool becomes hard and stuck in the rectum.
• Diverticulitis: Inflammation or infection of small pouches in the digestive tract.

> Warning: Stop taking Sevelamer Carbonate and call your doctor immediately if you experience any of these serious symptoms.

• Severe Constipation: If you go several days without a bowel movement, this could indicate a developing blockage.
• Severe Abdominal Pain or Swelling: This may be a sign of bowel perforation (a hole in the intestine) or ileus (lack of movement in the intestines).
• Difficulty Swallowing: If the tablet feels stuck in your throat or you have trouble getting food down.
• Black, Tarry, or Bloody Stools: This could indicate gastrointestinal bleeding or ulceration.
• Signs of an Allergic Reaction: Including rash, hives, swelling of the face, lips, or tongue, and difficulty breathing.

One of the primary concerns with long-term use of Sevelamer Carbonate is its potential to bind to substances other than phosphate.

• Vitamin Depletion: Sevelamer can bind to fat-soluble vitamins (Vitamins A, D, E, and K) and folic acid. Over time, this can lead to deficiencies. Vitamin K deficiency is of particular concern as it can interfere with blood clotting and worsen vascular calcification. Your doctor will monitor your vitamin levels and may prescribe supplements.
• Metabolic Changes: While Sevelamer Carbonate is better than the Hydrochloride version at maintaining bicarbonate levels, long-term monitoring of serum chloride and bicarbonate is still necessary to prevent metabolic acidosis.

As of 2026, there are no FDA black box warnings for Sevelamer Carbonate. However, the FDA has issued safety communications regarding the risk of serious gastrointestinal adverse events, particularly in patients with pre-existing GI motility disorders.

Report any unusual symptoms to your healthcare provider. Your medical team can help manage side effects by adjusting your dose or suggesting dietary changes.

Sevelamer Carbonate is a potent medication that requires careful medical supervision. Patients must be aware that this drug is only one part of a comprehensive treatment plan for CKD-MBD, which also includes a low-phosphorus diet and potentially other medications like Vitamin D analogs or calcimimetics.

No FDA black box warnings for Sevelamer Carbonate. However, it is essential to adhere to the safety precautions regarding gastrointestinal health.

• Gastrointestinal Disorders: Sevelamer Carbonate should be used with extreme caution in patients with active gastrointestinal (GI) disease. This includes patients with dysphagia (swallowing disorders), severe GI motility disorders (like severe constipation), or those who have recently had major GI surgery. The polymer can exacerbate these conditions and, in rare cases, lead to bowel perforation.
• Allergic Reactions: Patients with a known hypersensitivity to sevelamer carbonate or any of its excipients should avoid this medication. Anaphylaxis and other serious allergic reactions, though rare, have been reported.
• Vitamin and Folic Acid Deficiencies: Because Sevelamer may bind to fat-soluble vitamins (A, D, E, K) and folic acid, patients should be monitored for deficiencies. Pregnant women are at particular risk, as folic acid is vital for fetal development.
• Choking Hazard: The tablets are large and can expand if they become wet. They must be swallowed whole. Patients with a history of choking or narrow esophagi should use the powder formulation instead.

Patients taking Sevelamer Carbonate require regular laboratory testing to ensure safety and efficacy:

• Serum Phosphorus: Usually checked every 1-2 weeks during initial titration and then monthly once stable.
• Serum Calcium: To ensure the patient is not becoming hypocalcemic (low calcium) or hypercalcemic.
• Bicarbonate and Chloride: To monitor for metabolic acidosis.
• Vitamin Levels: Periodic checks of Vitamin D, A, E, K, and Folic Acid levels.

Sevelamer Carbonate is not known to cross the blood-brain barrier and does not typically cause drowsiness or cognitive impairment. It is generally considered safe to drive or operate machinery while taking this medication, provided you do not feel unwell due to gastrointestinal side effects.

There are no direct chemical interactions between Sevelamer Carbonate and alcohol. However, many alcoholic beverages (especially beer and certain dark spirits) are high in phosphorus. Excessive alcohol consumption can undermine the effectiveness of the medication in controlling phosphorus levels. Discuss your alcohol intake with your renal dietitian.

Do not stop taking Sevelamer Carbonate abruptly without consulting your nephrologist. Stopping the medication will likely result in a rapid rebound of serum phosphorus levels, which can increase the risk of cardiovascular events and bone pain. If the medication must be stopped due to side effects, your doctor will transition you to an alternative phosphate binder.

> Important: Discuss all your medical conditions, especially any history of bowel surgery or intestinal blockages, with your healthcare provider before starting Sevelamer Carbonate.

There are no drugs that are strictly contraindicated for use with Sevelamer Carbonate in the sense of causing a fatal reaction; however, the binding nature of the drug means it can render other life-saving medications completely ineffective if taken at the same time.

• Ciprofloxacin (Cipro): Sevelamer can reduce the bioavailability of ciprofloxacin by approximately 50%. This can lead to treatment failure for serious infections. Ciprofloxacin should be administered at least 2 hours before or 6 hours after Sevelamer.
• Mycophenolate Mofetil (CellCept): In transplant patients, Sevelamer can reduce the absorption of mycophenolate, potentially increasing the risk of organ rejection. These drugs must be separated by at least 2 hours.
• Levothyroxine (Synthroid): Sevelamer can bind to thyroid hormones in the gut, leading to hypothyroidism (underactive thyroid). Thyroid-stimulating hormone (TSH) levels should be monitored closely, and the doses should be separated by several hours.

• Cyclosporine and Tacrolimus: These immunosuppressants may have reduced levels when taken with Sevelamer. Blood levels of these drugs should be monitored closely by a transplant team.
• Anti-Arrhythmic Drugs: Medications like Amiodarone may have altered absorption. Close ECG monitoring may be required during initiation.
• Proton Pump Inhibitors (PPIs): Drugs like Omeprazole change the pH of the stomach, which might theoretically affect the binding capacity of Sevelamer, though clinical data on this is mixed.

Sevelamer Carbonate is intended to interact with food. However, the type of food matters:

• High-Phosphorus Foods: While Sevelamer binds phosphorus, it cannot neutralize an unlimited amount. A diet high in processed meats, dairy, and colas can overwhelm the medication's capacity.
• Fat-Soluble Vitamins: Taking vitamin supplements at the same time as Sevelamer may prevent the vitamins from being absorbed. Supplements should be taken at least 3 hours away from Sevelamer doses.

• Calcium Supplements: While often used together, taking them at the exact same time might reduce the efficiency of phosphate binding.
• Multivitamins: Should be taken at a different time of day (e.g., at bedtime) to ensure the Sevelamer does not bind the vitamins.

Sevelamer Carbonate does not typically interfere with the chemical assays used in laboratory testing. However, by changing the levels of phosphorus, calcium, and bicarbonate in the blood, it will naturally alter these lab results as part of its therapeutic effect.

Management Strategy: The general rule for managing interactions with Sevelamer Carbonate is the "1 and 3 rule." Take other medications at least 1 hour before or 3 hours after your Sevelamer dose. This allows the other medication to be absorbed before the Sevelamer polymer reaches that section of the gut.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers and vitamins.

Sevelamer Carbonate is strictly contraindicated in the following scenarios:

1. 1Bowel Obstruction: Patients with a known or suspected intestinal obstruction must not take Sevelamer Carbonate. Because the medication is a non-digestible polymer that adds bulk to the stool, it can turn a partial obstruction into a complete, life-threatening blockage or cause a bowel rupture.
2. 2Hypersensitivity: Anyone with a documented severe allergic reaction to sevelamer carbonate, sevelamer hydrochloride, or any component of the formulation (such as the film coating or suspension agents) should not use the drug.

Healthcare providers must perform a careful risk-benefit analysis for patients with:

• Severe Gastrointestinal Motility Disorders: This includes patients with gastroparesis (delayed stomach emptying) or severe, chronic constipation. The risk of fecal impaction or bowel perforation is significantly higher in these individuals.
• Major Gastrointestinal Surgery: Patients who have recently undergone bowel surgery may have adhesions or narrowing that increase the risk of the polymer becoming stuck.
• Dysphagia: Patients with difficulty swallowing are at risk of the tablet expanding in the esophagus. For these patients, the powder suspension is the only appropriate form, and even then, caution is required.

Patients who have had an allergic reaction to Sevelamer Hydrochloride (Renagel) are highly likely to be allergic to Sevelamer Carbonate (Renvela), as the active polymer (sevelamer) is identical in both formulations. There is no known cross-sensitivity with other classes of phosphate binders, such as Lanthanum Carbonate or Sucroferric Oxyhydroxide.

> Important: Your healthcare provider will evaluate your complete medical history, especially any history of 'lazy bowel' or previous abdominal surgeries, before prescribing Sevelamer Carbonate.

Sevelamer Carbonate is classified as a drug where human data is limited. Because the drug is not absorbed systemically, it is not expected to be directly teratogenic (causing birth defects) to the fetus. However, its secondary effect of binding folic acid and fat-soluble vitamins is a major concern. Folic acid deficiency during pregnancy is a known cause of neural tube defects. If Sevelamer Carbonate is used during pregnancy, aggressive monitoring of vitamin levels and increased supplementation of folic acid are mandatory. The American College of Obstetricians and Gynecologists (ACOG) suggests that maintaining normal phosphorus levels is vital for maternal health, but the risks of nutrient depletion must be balanced.

Sevelamer Carbonate is not absorbed by the mother and therefore cannot be excreted into breast milk. It is generally considered safe for use during breastfeeding. However, the mother should continue to be monitored for vitamin deficiencies to ensure that the nutritional quality of the breast milk remains adequate for the infant.

Sevelamer Carbonate is FDA-approved for children aged 6 years and older. The primary concern in the pediatric population is the impact on growth. Chronic hyperphosphatemia and the resulting bone disease can lead to stunted growth and skeletal deformities. While Sevelamer is effective at lowering phosphorus in children, long-term studies on its impact on bone mineral density in growing children are still ongoing. It is not recommended for children under the age of 6.

In clinical trials, approximately 28% of subjects were 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. However, elderly patients are more prone to constipation and have a higher prevalence of diverticular disease. Therefore, the risk of GI complications like bowel obstruction should be monitored more closely in this age group.

Sevelamer Carbonate is specifically designed for patients with end-stage renal disease (ESRD). While it is effective, it does not treat the underlying kidney failure. Patients with Stage 3 or 4 CKD (not yet on dialysis) may use the drug, but the FDA-approved labeling is focused on the dialysis population. No dose adjustment is needed for the degree of renal failure, as the drug's action is entirely independent of kidney function.

There is no need for dose adjustment in patients with liver disease. Since the drug is not processed by the liver, Child-Pugh scores do not affect the pharmacokinetics of Sevelamer Carbonate.

> Important: Special populations, particularly pregnant women and the elderly, require individualized medical assessment and more frequent laboratory monitoring.

Sevelamer Carbonate is a non-absorbed, high-molecular-weight, cross-linked polymer. It contains multiple primary and secondary amines, each separated by one carbon from the polymer backbone. In the physiological environment of the gut, these amines become partially protonated. The resulting positively charged polymer acts as an ion-exchange resin. It binds to the negatively charged phosphate ions (HPO4^2- and H2PO4^-) through a combination of ionic bonding and hydrogen bonding. By binding phosphate in the dietary bolus within the stomach and small intestine, Sevelamer prevents the transport of phosphate across the intestinal epithelium into the blood.

The pharmacodynamic effect of Sevelamer is purely local. The dose-response relationship is well-documented: higher doses of Sevelamer bind more phosphate, up to a saturation point. The onset of effect occurs with the very first meal taken with the medication, although it may take 1-2 weeks of consistent use to see a significant drop in serum phosphorus levels. Sevelamer also exhibits bile-acid sequestering activity, which can lower LDL cholesterol by approximately 15-30%.

| Parameter | Value |

|---|---|

| Bioavailability | 0% (Not absorbed) |

| Protein Binding | 0% (Systemic) |

| Half-life | N/A (Remains in GI tract) |

| Tmax | N/A |

| Metabolism | None (Not a substrate for CYP enzymes) |

| Excretion | Fecal (100% recovered as unchanged polymer) |

• Molecular Formula: (C6H11N·H2CO3)z (where z is a large number representing the cross-linked nature)
• Molecular Weight: Extremely high (polymeric)
• Solubility: Insoluble in water and organic solvents; forms a suspension.
• Structure: It is a poly(allylamine hydrochloride) cross-linked with epichlorohydrin, where the carbonate salt replaces the hydrochloride salt.

Sevelamer Carbonate is classified as a Phosphate Binder and specifically as a Non-Calcium, Non-Metal Polymeric Binder. It is often compared to other binders like Calcium Acetate (PhosLo), Lanthanum Carbonate (Fosrenol), and Sucroferric Oxyhydroxide (Velphoro).